An update on bimatoprost in glaucoma therapy

References

• QUIGLEY HA: Number of people with glaucoma worldwide. Br. .1. Ophthalmol (1996) 80:389–393.
   PubMed Web of Science ®Google Scholar
• THYLEFORS B, NE.GREL AD: The global impact of glaucoma. Bull. World Health Org. (1994) 72:323–326.
   PubMed Web of Science ®Google Scholar
• MAO LK, STEWART WC, SHIELDS MB: Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am. J. Ophthalmol (1991) 111:51–55.
   PubMed Web of Science ®Google Scholar
• LICHTER PR, MUSCH DC, GILLESPIE BW et al.: Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology (2001) 108:1943–1953.
   PubMed Web of Science ®Google Scholar
• SHIRAKASHI M, IWATA K, SAWAGUCHI S, ABE H, NANBA K: Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up. Ophthalmologica (1993) 207:1–5.
   PubMed Web of Science ®Google Scholar
• The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol (2000) 130:429–440.
   Google Scholar
• Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-tension Glaucoma Study Group. Am. I. Ophthalmol (1998) 126:487-497. Published erratum appears in Am. I. Ophthalmol (1999) 127:120.
   Google Scholar
• GONZALEZ I, PABLO LE, PUEYO M et al.: Assessment of diurnal tensional curve in early glaucoma damage. Int. Ophthalmol (1996–97) 20:113–115.
   Google Scholar
• ASRANI S, ZEIMER R, WILENSKY J, GIESER D, VITALE S, LINDENMUTH K: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma (2000) 9:134–142.
   PubMed Web of Science ®Google Scholar
• SPAETH GL, MARQUES PEREIRA ML: How does resetting intraocular pressure help optic nerve function? Eye (2000) 14:476–487.
   PubMedGoogle Scholar
• KASS MA, GORDON MO, HOFF MR et al.: Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch. Ophthalmol (1989) 107:1590–1598.
   PubMedGoogle Scholar
• EPSTEIN DL, KRUG JH Jr, HERTZMARK E, REMIS LL, EDELSTEIN DJ: A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology (1989) 96:1460–1467.
   PubMed Web of Science ®Google Scholar
• SCHULZER M, DRANCE SM, DOUGLAS GR: A comparison of treated and untreated glaucoma suspects. Ophthalmology (1991) 98:301–307.
   PubMedGoogle Scholar
• KASS MA, HEUER DK, HIGGINBOTHAM EJ et al: The ocular hypertension treatment study: a randomized trial determines that topical medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol (2002) 120:701–713.
   PubMed Web of Science ®Google Scholar
• LUI JHK, KRIPKE DF, TWA MD et al.: Twenty-four-hour pattern of intraocular pressure in the aging population. Invest. Ophthalmol Vis. Sci. (1999) 40:2912–2917.
   PubMed Web of Science ®Google Scholar
• DAVID R, ZANGWILL L, BRISCOE D, DAGAN M, YAGEV R, YASSUR Y: Diurnal intraocular pressure variations: an analysis of 690 diurnal curves. Br. J. Ophthalmol (1992) 76:280–283.
   PubMed Web of Science ®Google Scholar
• SACCA SC, ROLANDO M, MARLETTA A et al.: Fluctuations of intraocular pressure during the day in open-angle glaucoma, normal-tension glaucoma and normal subjects. Ophthalmologica (1998) 212:115–119.
   PubMed Web of Science ®Google Scholar
• ZEIMER RC, WILENSKY JT, GIESER DK: Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients. Ophthalmology (1990) 97:547–550.
   PubMed Web of Science ®Google Scholar
• BRUBAKER RF: Mechanism of action of bimatoprost (Lumigan). Surv. Ophthalmol (2001) 45\(Suppl. 4):S347–S351.
   Google Scholar
• ••Describes the benefits of lowering TOP byenhancing tonographic outflow facility.
   Google Scholar
• SINGH K, SPAETH G, ZIMMERMAN T, MINCKLER D: Target pressure - glaucomatologists' holey grail. Ophthalmology (2000) 107:629–630.
   PubMed Web of Science ®Google Scholar
• ZEYEN T: Target pressures in glaucoma. Bull. Soc. Belga Ophtalmol. (1999) 274:61–65.
   PubMedGoogle Scholar
• American Academy of Ophthalmology Preferred Practice Pattern': Primary Open-Angle Glaucoma. (2000).
   Google Scholar
• CANTOR LB: Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management. Expert Opin. Investig. Drugs. (2001) 10(4):721–731.
   PubMed Web of Science ®Google Scholar
• DIGGORY P, FRANKS W: Medical treatment of glaucoma - a reappraisal of the risks. Br. J. Ophthalmol (1996) 80:85–89.
   PubMed Web of Science ®Google Scholar
• GRANT WM: Clinical measurements of aqueous outflow. Arch. Ophthalmol (1951) 46:113–131.
   PubMedGoogle Scholar
• BECKER B: Comment on: large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J. Glaucoma. (2000) 9(6):487–488.
   PubMedGoogle Scholar
• WOODWARD DF, KRAUSS AH-P, CHEN J et al: The pharmacology of bimatoprost (Lumigan"). Surv. Ophthalmol (2001) 45\(Suppl. 4):5337–5345.
   Google Scholar
• •Review of the pharmacology of bimatoprost.
   Google Scholar
• LAIBOVITZ RA, VANDENBURGH AM, FELIX C et al.: Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy and safety evaluation of a novel compound for glaucoma management. Arch. Ophthalmol (2001) 119(7):994–1000.
   PubMedGoogle Scholar
• DUBINER H, COOKE D, DIRKS M, STEWART WC, VANDENBURGH AM, FELIX C: Efficacy and safety of bimatoprost in patients with elevated IOP: a 30-day comparison with latanoprost. Surv. Ophthalmol (2001) 45\(Suppl. 4):5353–5360.
   Google Scholar
• BRANDT JD, VANDENBURGH AM, CHEN K, WHITCUP SM: Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology (2001) 108(6):1023–1031.
   PubMed Web of Science ®Google Scholar
• SHERWOOD M, BRANDT J: Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol (2001) 45\(Suppl. 4):5361–5368.
   Google Scholar
• BRUBAKER RF, SCHOFF EO, NAU CB et al: Effects of AGN 192024, anew ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol (2001) 131:19–24.
   PubMed Web of Science ®Google Scholar
• SHARIF NA, WILLIAMS GW, KELLY CR: Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur. Pharmacol (2001) 432:211–213.
   PubMed Web of Science ®Google Scholar
• WANG R-F, SERLE JB, GAGLIUSO D, MITTAG TW, POD OS TW: Effect of latanoprost (L) or bimatoprost (B) alone and in combination on intraocular pressure (TOP) in glaucomatous monkey eyes. Prevented at the Annual Meeting of the Association for Vision Research and Ophthalmology Fort Lauderdale, FL, USA (2002):4070.
   Google Scholar
• DAHLIN DC, BERGAMINI MVW, CURTIS MA, DEAN TR, KIEHLBAUCH CC, CHASTAIN JE: Bimatoprost hydrolysis to 17-phenyl PGF2 by rabbit and monkey ocular tissues, in viva Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology Fort Lauderdale, FL, USA (2002):4109.
   Google Scholar
• WOODWARD DF, MADHU C, BURK RIVI et al: AGN 192024 (Lumigan"): a synthetic prostamide analog that lowers primate intraocular pressure by virtue of its inherent pharmacological activity. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology Fort Lauderdale, FL, USA (2002):4110.
   Google Scholar
• MAXEY KM, JOHNSON J, CAMRAS CB, LABRECQUE J: The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Presented at the Annual Meeting of the American Glaucoma Society San Juan, Puerto Rico (2002).
   Google Scholar
• KRAUSS AH-P, CHEN J, ANDREWS SW, TAN G-LIUD, NILSSON SFE, WOODWARD DF: The ocular pharmacology and bioavailability of AGN 192024 (Lumigan), a novel ocular hypotensive agent. Prevented at the Annual Meeting of the Association for Vision Research and Ophthalmology Fort Lauderdale, FL USA (2001):4465.
   Google Scholar
• SJOQUIST B, JOHANSSON A, STJERNSCHANTZ J: Pharmacokinetics of latanoprost in the cynomolgus monkey. 3rd communication: tissue distribution after topical administration on the eye studied by whole body autoradiography. Arzneimittelforschung (1999) 49:240–249.
   Google Scholar
• CHEETHAM JK, TAN G-LIUD, YU Z et al.: Long-term systemic exposure of Lumigan in patients with glaucoma or ocular hypertension. Presented at theAnnual Meeting of the Association for Vision Research and Ophthalmology Fort Lauderdale, FL, USA (2002):4108.
   Google Scholar
• HIGGINBOTHAM EJ, GOLDBERG I, SCHUMAN JS et al.: One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch. Ophthalmol (2002)120:1286–1293.
   PubMed Web of Science ®Google Scholar
• ••Shows that the efficacy of bimatoprost issustained with long-term treatment.
   Google Scholar
• GANDOLFI S, SIMMONS ST, STURM R, CHEN K, VANDENBURGH AM: Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv. Thar. (2001) 18(3):110–121.
   PubMed Web of Science ®Google Scholar
• NOECKER RS, DIRKS MS, CHOPLIN NT, BERNSTEIN P, BATOOSINGH AL, WHITCUP SM: A six-month randomized clinical trial comparing the TOP-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. The Bimatoprost/Latanoprost Study Group. Am.,/ Ophthalmol (2003): (In press).
   Google Scholar
• ••Shows superior TOP-lowering efficacy ofbimatoprost compared with latanoprost.
   Google Scholar
• COLEMAN AL, VANDENBURGH AM, BERNSTEIN P, WHITCUP SM: A 3-month comparison of bimatoprost (LumiganTm) with timolol/dorzolamide (CosoptTm) in patients with glaucoma or ocular hypertension. Prevented at the American Academy of Ophthalmology New Orleans, LA, USA (2001):322.
   Google Scholar
• WALTERS TR, DUBINER HB, CARPENTERS, VANDENBURGH AM: 24-Hour diurnal comparison of once-daily dosing with bimatoprost 0.03%, timolol-XETm, and latanoprost 0.005%. Prevented at the American Academy of Ophthalmology New Orleans, LA, USA (2001):233.
   Google Scholar
• ••Shows that bimatoprost provides 24-hTOP control.
   Google Scholar
• DIRKS MS: Bimatoprost as monotherapyin patients previously treated with timolol/latanoprost dual therapy. Presented at the Annual Meeting of the American Glaucoma Society (2002) San Juan, Puerto Rico.
   Google Scholar
• MELAMED S, BOSSAWSKA I, LAROCH C; BIMATOPROST ADJUNCTIVE TO TIMOLOL STUDY GROUP: Effectiveness of bimatoprost (LUMIGANTm) as adjunctive therapy with topical13-blockers in patients with glaucoma or ocular hypertension: a 3-month, multi-center, double-masked, randomized, vehicle-controlled trial with double-masked extension of bimatoprost treatment to 1 year. Prevented at the Annual Meeting of the Association for Vision Research and Ophthalmology Fort Lauderdale, FL, USA (2002):1068.
   Google Scholar
• FRENKEL REP: Efficacy of bimatoprost 0.03% as adjunctive therapy in glaucoma patients using latanoprost 0.005%. Presented at the Annual Meeting of the American Glaucoma Society San Juan, Puerto Rico (2002).
   Google Scholar
• LEE DA, GROSS R, MUNDORF TK; LUMIGAN EARLY EXPERIENCE STUDY GROUP: Efficacy and safety of bimatoprost 0.03% (LUMIGANTm) in a large-scale, open-label clinical trial. Presented at the Annual Meeting of the Association for Vision Research and Ophthalmology Fort Lauderdale, FL, USA (2002):4105.
   Google Scholar
• WAND M, GAUDIO AR: Cystoid macular edema associated with ocular hypotensive lipids. Am. I Ophthalmol. (2002) 133(3):403–405.
   PubMed Web of Science ®Google Scholar
• KROLL DM, SCHUMAN JS: Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am. J. Ophthalmol (2002) 133(3):401–403.
   PubMed Web of Science ®Google Scholar
• SCHERER WJ: A retrospective review of non-responders to latanoprost. Owl Pharmacol Thar. (2002) 18(3):287–291.
   Google Scholar
• NETLAND PA, LANDRY T, SULLIVAN K et al.: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. I Ophthalmol (2001) 132:472–484.
   PubMed Web of Science ®Google Scholar
• TORIS CB, CAMRAS CB, YABLONSKI ME: Effects of PhXA41, a new prostaglandin Fac analog, on aqueous humor dynamics in human eyes. Ophthalmology (1993) 100:1297–1304.
   PubMed Web of Science ®Google Scholar
• SAITO M, TAKANO R, SHIRATO S: Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am. .1. Ophthalmol (2001) 132:485–489.
   PubMed Web of Science ®Google Scholar
• ZIAI N, DOLAN JW, KACERE RD, BRUBAKER RF: The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol (1993) 111:1351–1358.
   PubMed Web of Science ®Google Scholar
• MORGAN PV, PRONIUK S, BLANCHARD J, NOECKER RJ: Effect of temperature and light on the stability of latanoprost and its clinical relevance. J. Glaucoma. (2001) 10:401–405.
   PubMedGoogle Scholar